Plain-English translation of NCT07137910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II clinical trial testing a medication called injection in people with chronic hepatitis B who have already been treated with other antiviral drugs. Researchers want to see if this medication is effective at reducing the virus and safe for patients to use. The study will include 60 participants at multiple medical centers.
Many people with chronic hepatitis B have already tried standard antiviral medications, but some may not respond well enough or may need additional treatment options. This trial is exploring whether this medication could be a helpful new choice for these patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive injections of the new medication at a medical center as part of this open-label study (meaning both you and your doctors know what treatment you are receiving). You will have regular clinic visits for blood tests and health assessments to monitor how well the medication is working and whether you experience any side effects. The study will track your virus levels and liver function over time to evaluate the treatment's effectiveness and safety.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Ausper Biopharma Co., Ltd.
Enrollment target
~60 participants
Started
September 2025
Primary completion
December 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lu
The First Hospital of Jilin University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.